GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the U.S.
Company appoints five new independent directors to reconstituted board
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
Man lost 54 Kgs in 6 months with MGB procedure
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
The product will be manufactured at Lupin’s facility in Goa, India.
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Subscribe To Our Newsletter & Stay Updated
